Trials / Completed
CompletedNCT02770040
Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Austin Health · Other Government
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify whether an Accelerated or Intensified Infliximab induction regimen is superior to Standard induction in Acute Severe Ulcerative Colitis in an open label multi-centre randomised controlled trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused |
Timeline
- Start date
- 2016-07-18
- Primary completion
- 2021-10-01
- Completion
- 2022-09-07
- First posted
- 2016-05-12
- Last updated
- 2024-10-08
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT02770040. Inclusion in this directory is not an endorsement.